Stelara 90 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DR26FCPC2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,584
Award facts
- Contract value 100% obligated
- $16,584.13 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $16,584.13 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of STELARA 90 mg/ml syringes. The contract was awarded on November 7, 2025, with an ultimate completion date of December 2, 2025, and carries no set-aside designation, indicating the award was made through full and open competition. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a comprehensive $30.3 billion acquisition strategy designed to support recurring pharmaceutical supply needs across Department of Defense military healthcare facilities worldwide.
As a critical regional prime vendor contractor under PPV-G GEN V, DMS Pharmaceutical Group is authorized to supply a comprehensive range of pharmaceutical products including branded and generic prescription medications, biologics, vaccines, and medical consumables to support DOD healthcare operations. The company's IDC, valued at $499,999,999 and extending through December 31, 2036, positions it to serve as a key pharmaceutical supplier for military medical systems globally. DMS Pharmaceutical Group's selection reflects its demonstrated capability to deliver specialized pharmaceutical products efficiently to federal military healthcare facilities, with the STELARA delivery order representing one of numerous individual issuances under this broader prime vendor contract framework.
Quick answers
Who was awarded contract SPE2DR26FCPC2?
SPE2DR26FCPC2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 7, 2025.
How much is contract SPE2DR26FCPC2 worth?
The government has obligated $16,584 on SPE2DR26FCPC2.
Is contract SPE2DR26FCPC2 an order under another contract?
Yes. SPE2DR26FCPC2 is a delivery order under SPE2DR25D9131, an indefinite delivery contract.
Was contract SPE2DR26FCPC2 competed?
The extent of competition for SPE2DR26FCPC2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award